Obsessive-compulsive disorder: Diagnosis and management

American Family Physician

Volumn 80, Issue 3, 2009, Pages 239-245

  Fenske, Jill N ^a,b   Schwenk, Thomas L ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Chelsea Health Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; CITALOPRAM; CLOMIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; HYPERICUM PERFORATUM EXTRACT; MIRTAZAPINE; OLANZAPINE; PAROXETINE; QUETIAPINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ALTERNATIVE MEDICINE; ANTICHOLINERGIC EFFECT; CLINICAL TRIAL; COGNITIVE THERAPY; COMORBIDITY; CONTROLLED CLINICAL TRIAL; DEPRESSION; DRUG DOSE REGIMEN; DRUG EFFICACY; HEART ARRHYTHMIA; HUMAN; OBSESSIVE COMPULSIVE DISORDER; PATHOGENESIS; PATIENT EDUCATION; PRACTICE GUIDELINE; PREVALENCE; PRIMARY MEDICAL CARE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REVIEW; SEIZURE; SIDE EFFECT; SUICIDAL IDEATION;

EID: 69149090119     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication [published correction appears in Arch Gen Psychiatry. 2005;62(7):709]. Arch Gen Psychiatry. 2005;62(6):617-627.
2. Koran LM. Quality of life in obsessive-compulsive disorder. Psychiatr Clin North Am. 2000;23(3):509-517.
3. Pinto A, Mancebo MC, Eisen JL, Pagano ME, Rasmussen SA. The Brown Longitudinal Obsessive Compulsive Study: clinical features and symptoms of the sample at intake. J Clin Psychiatry. 2006;67(5):703-711. (Pubitemid 43946176)
4. Friedlander L, Desrocher M. Neuroimaging studies of obsessive-compulsive disorder in adults and children. Clin Psychol Rev. 2006;26(1):32-49. (Pubitemid 41803610)
5. Pauls DL. The genetics of obsessive compulsive disorder: a review of the evidence. Am J Med Genet C Semin Med Genet. 2008;148(2):133-139. (Pubitemid 351705130)
6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed., text revision. Washington, DC: American Psychiatric Association; 2000.
7. Chabane N, Delorme R, Millet B, Mouren MC, Leboyer M, Pauls D. Early-onset obsessive-compulsive disorder: a subgroup with a specific clinical and familial pattern? J Child Psychol Psychiatry. 2005;46(8):881-887. (Pubitemid 41633094)
8. Rosario-Campos MC, Leckman JF, Mercadante MT, et al. Adults with early-onset obsessive-compulsive disorder. Am J Psychiatry. 2001;158(11):1899- 1903.
9. Wheaton M, Timpano KR, Lasalle-Ricci VH, Murphy D. Characterizing the hoarding phenotype in individuals with OCD: associations with comorbidity, severity and gender. J Anxiety Disord. 2008;22(2):243-252.
10. Coles ME, Frost RO, Heimberg RG, Rhéaume J. "Not just right experiences": perfectionism, obsessive-compulsive features and general psychopathology. Behav Res Ther. 2003;41(6):681-700. (Pubitemid 36539351)
11. Rasmussen SA, Eisen JL. The epidemiology and clinical features of obsessive compulsive disorder. Psychiatr Clin North Am. 1992;15(4):743-758. (Pubitemid 23032171)
12. McKay D, Abramowitz JS, Calamari JE, et al. A critical evaluation of obsessive-compulsive disorder subtypes: symptoms versus mechanisms. Clin Psychol Rev. 2004;24(3):283-313. (Pubitemid 38881544)
13. Nelson EA, Abramowitz JS, Whiteside SP, Deacon BJ. Scrupulosity in patients with obsessive-compulsive disorder: relationship to clinical and cognitive phenomena. J Anxiety Disord. 2006;20(8):1071-1086. (Pubitemid 44667383)
14. Diniz JB, Rosario-Campos MC, Hounie AG, et al. Chronic tics and Tourette syndrome in patients with obsessive-compulsive disorder. J Psychiatr Res. 2006;40(6):487-493.
15. McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH. Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder. A double-blind, placebo-controlled study in patients with and without tics. Arch Gen Psychiatry. 1994;51(4):302-308.
16. Canadian Psychiatric Association. Clinical practice guidelines. Management of anxiety disorders [published correction appears in Can J Psychiatry. 2006;51(10):623]. Can J Psychiatry. 2006;51(8 suppl 2):9S-91S.
17. Foa EB, Huppert JD, Leiberg S, et al. The Obsessive-Compulsive Inventory: development and validation of a short version. Psychol Assess. 2002;14(4):485-496. (Pubitemid 35440493)
18. Storch EA, Kaufman DA, Bagner D, et al. Florida Obsessive-Compulsive Inventory: development, reliability, and validity [published correction appears in J Clin Psychol. 2007;63(12):1265]. J Clin Psychol. 2007;63(9):851-859.
19. Kamath P, Reddy YC, Kandavel T. Suicidal behavior in obsessive-compulsive disorder. J Clin Psychiatry. 2007;68(11):1741-1750.
20. Rush JA. Handbook of Psychiatric Measures. Washington, DC: American Psychiatric Association; 2000:572-574.
21. Koran LM, Hanna GL, Hollander E, Nestadt G, Simpson HB, for the American Psychiatric Association. Practice guideline for the treatment of patients with obsessive-compulsive disorder. Am J Psychiatry. 2007; 164(7 suppl):5-53.
22. Gava I, Barbui C, Aguglia E, et al. Psychological treatments versus treatment as usual for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev. 2007;(2):CD005333. (Pubitemid 351805880)
23. Fisher PL, Wells A. How effective are cognitive and behavioral treatments for obsessive-compulsive disorder? A clinical significance analysis. Behav Res Ther. 2005;43(12):1543-1558. (Pubitemid 41472065)
24. Eddy KT, Dutra L, Bradley R, Westen D. A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev. 2004;24(8):1011-1030. (Pubitemid 40247306)
25. Soomro GM, Altman D, Rajagopal S, Oakley-Browne M. Selective serotonin re-uptake inhibitors (SSRIs) versus placebo for obsessive compulsive disorder (OCD). Cochrane Database Syst Rev. 2008;(1):CD001765. (Pubitemid 351807691)
26. Adams SM, Miller KE, Zylstra RG. Pharmacologic management of adult depression. Am Fam Physician. 2008;77(6):785-792.
27. Simpson HB, Liebowitz MR, Foa EB, et al. Post-treatment effects of exposure therapy and clomipramine in obsessive-compulsive disorder. Depress Anxiety. 2004;19(4):225-233.
28. Denys D, van der Wee N, van Megen HJ, Westenberg HG. A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. J Clin Psychopharmacol. 2003;23(6):568-575. (Pubitemid 37443188)
29. Koran LM, Gamel NN, Choung HW, Smith EH, Aboujaoude EN. Mirtazapine for obsessive-compulsive disorder: an open trial followed by double-blind discontinuation. J Clin Psychiatry. 2005;66(4):515-520. (Pubitemid 40593581)
30. Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder [published correction appears in Mol Psychiatry. 2006;11(8):795]. Mol Psychiatry. 2006;11(7):622-632.
31. Brown RA, Abrantes AM, Strong DR, et al. A pilot study of moderate-intensity aerobic exercise for obsessive compulsive disorder. J Nerv Ment Dis. 2007;195(6):514-520.
32. Hanstede M, Gidron Y, Nyklícek I. The effects of a mindfulness intervention on obsessive-compulsive symptoms in a non-clinical student population. J Nerv Ment Dis. 2008;196(10):776-779.
33. Kobak KA, Taylor LV, Bystritsky A, et al. St John's wort versus placebo in obsessive-compulsive disorder: results from a double-blind study. Int Clin Psychopharmacol. 2005;20(6):299-304. (Pubitemid 41475318)